{"id":7143,"date":"2021-11-05T14:20:07","date_gmt":"2021-11-05T14:20:07","guid":{"rendered":"https:\/\/factor-h.org\/?p=7143"},"modified":"2021-11-05T14:20:07","modified_gmt":"2021-11-05T14:20:07","slug":"meet-ignacio-a-crl-interview","status":"publish","type":"post","link":"https:\/\/factor-h.org\/pt\/meet-ignacio-a-crl-interview","title":{"rendered":"Atender Ignacio \u2013 uma CRL entrevista"},"content":{"rendered":"<p>Conhe\u00e7a nosso segundo disruptor Ignacio Mu\u00f1oz-Sanju\u00e1n. Descobrir como <a href=\"https:\/\/www.criver.com\/insights\/vital-science-podcast\/s3-e01-synergistic-approach-treating-huntingtons-disease\" target=\"_blank\" rel=\"noopener\">trabalho de In\u00e1cio<\/a> est\u00e1 permitindo que as organiza\u00e7\u00f5es desenvolvam novas terapias para a doen\u00e7a de Huntington. Por meio de seu trabalho de descoberta de medicamentos na CHDI Foundation, uma organiza\u00e7\u00e3o sem fins lucrativos, Ignacio alimenta sua motiva\u00e7\u00e3o para descobrir poss\u00edveis tratamentos e uma eventual cura para essa doen\u00e7a transgeracional incapacitante, fazendo parceria com v\u00e1rias organiza\u00e7\u00f5es com diferentes conhecimentos t\u00e9cnicos, como Charles River.<\/p>\n\n\n\n<p>Encontre o link para a entrevista <a href=\"https:\/\/www.criver.com\/about-us\/disruptors\/meet-ignacio?region=3601\" data-type=\"URL\" data-id=\"https:\/\/www.criver.com\/about-us\/disruptors\/meet-ignacio?region=3601\">aqui<\/a><\/p>\n\n\n\n\n\n<p><\/p>","protected":false},"excerpt":{"rendered":"<p>Meet our second disruptor Ignacio Mu\u00f1oz-Sanju\u00e1n. Find out how Ignacio\u2019s work is enabling organizations to develop novel therapies for Huntington\u2019s disease. Through his drug discovery work at CHDI Foundation, a nonprofit organization, Ignacio fuels his motivation to uncover potential treatments and an eventual cure for this crippling transgenerational disease by partnering with multiple organizations with [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":7145,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[64,105,98,71,9,41],"tags":[],"class_list":["post-7143","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-advocacy","category-for-the-press","category-in-the-press","category-media-campaigns","category-general-news","category-us"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/factor-h.org\/pt\/wp-json\/wp\/v2\/posts\/7143","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/factor-h.org\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/factor-h.org\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/factor-h.org\/pt\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/factor-h.org\/pt\/wp-json\/wp\/v2\/comments?post=7143"}],"version-history":[{"count":1,"href":"https:\/\/factor-h.org\/pt\/wp-json\/wp\/v2\/posts\/7143\/revisions"}],"predecessor-version":[{"id":10670,"href":"https:\/\/factor-h.org\/pt\/wp-json\/wp\/v2\/posts\/7143\/revisions\/10670"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/factor-h.org\/pt\/wp-json\/wp\/v2\/media\/7145"}],"wp:attachment":[{"href":"https:\/\/factor-h.org\/pt\/wp-json\/wp\/v2\/media?parent=7143"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/factor-h.org\/pt\/wp-json\/wp\/v2\/categories?post=7143"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/factor-h.org\/pt\/wp-json\/wp\/v2\/tags?post=7143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}